Axitinib With or Without Anti-OX40 Antibody PF-04518600 in Treating Patients With Metastatic Kidney Cancer
Status:
Recruiting
Trial end date:
2023-07-19
Target enrollment:
Participant gender:
Summary
This randomized phase II trial studies how well axitinib with or without anti-OX40 antibody
PF-04518600 work in treating patients with kidney cancer that has spread to other parts of
the body. Biological therapies, such as anti-OX40 antibody PF-04518600, use substances made
from living organisms that may may stimulate the immune system in different ways and stop
tumor cells from growing. Axitinib may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth. Giving axitinib with or without anti-OX40 antibody
PF-04518600 may work better in treating patients with kidney cancer.